Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

July 8, 2019

Lynparza Approved in Japan as First-Line Maintenance Therapy for Advanced OC

News

Lynparza (olaparib) has been approved in Japan as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer that is responding, partially or completely, to their initial chemotherapy, AstraZeneca and Merck ... Read more

May 29, 2019May 29, 2019

Grant Lets Researchers Study OC Patients’ Responses to PARP Inhibitors

News

Researchers at Michigan State University (MSU) were granted $50,000 to investigate why only a fraction of ovarian cancer patients respond to treatment with PARP inhibitors. The grant, awarded by ... Read more

May 8, 2019

Lynparza Recommended for Approval in Europe for BRCA-mutated Advanced OC

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended that Lynparza (olaparib) be approved as a first-line maintenance therapy for women ... Read more

April 24, 2019

Surgeons Will Test LUM Imaging System to Better Detect Ovarian, Other Cancer Cells

News

Lumicell is assessing its LUM Imaging System as a means to help surgeons better detect cancer cells that spread into the peritoneum — the membrane lining the abdominal cavity ... Read more

March 29, 2019

Phase 3 Trial Launched to Test TTFields-Taxol Combo on Platinum-resistant Ovarian Cancer

News

Novocure has initiated a Phase 3 trial investigating its Tumor Treating Fields (TTFields) — a method that uses electric fields to disrupt cell division — in combination with Taxol ... Read more

March 27, 2019

Patients with Platinum-sensitive Ovarian Cancer Live Longer on SOTIO’s Immunotherapy, Trial Shows

News

Adding SOTIO’s ovarian cancer immunotherapy DCVAC/OvCa to standard second-line chemotherapy significantly extends the lives of women with advanced ovarian cancer who initially responded to their first-line chemotherapy, a Phase ... Read more

March 22, 2019

Low White Blood Cell Count May Help Predict Some Ovarian Cancer Outcomes

News

A reduced number of lymphocytes — one of the main types of immune cells — in advanced ovarian cancer patients before treatment is linked with a higher risk of ... Read more

February 6, 2019

Bavencio Shows Promise in Heavily Treated Ovarian Cancer Patients in Phase 1b Trial

News

Immune checkpoint inhibitor Bavencio (avelumab) has an acceptable safety profile and shows some anti-tumor activity among heavily pretreated ovarian cancer patients, according to a Phase 1b trial. Findings from the trial were ... Read more

February 4, 2019February 6, 2019

Phase 1 Trial Testing IMV’s Tailored Immunotherapy Doses First Ovarian Cancer Patient

News

IMV’s Phase 1 clinical trial evaluating a personalized immunotherapy that targets mutated proteins called neoepitopes in ovarian cancer patients has started dosing participants, the company announced. “The first immunization of ... Read more

January 30, 2019

Rubraca Maintenance Approved in Europe for Relapsed Ovarian Cancer

News

The European Commission has extended Rubraca‘s (rucaparib) approval as a maintenance therapy for women with advanced, relapsed ovarian cancer who are in complete or partial response to platinum-based chemotherapy. This ... Read more

Pin It on Pinterest